{
    "abstract": "Background: Tick borne encephalitis (TBE) endemic zones are expanding. We previously evaluated long term persistence of antibody 5 years after the first booster immunization following different primary immunization schedules with the polygeline-free inactivated TBE vaccine (TBEvac) in adults and adolescents. Here, we report anti-TBE virus (TBEV) antibody persistence from 6 to 10 years post-booster administration. Methods: This was a phase IV, open-label, single-center, second extension study (NCT01562444), conducted in Czechia. Healthy adults and adolescents \u226512 years who had received 3 different primary vaccination schedules (rapid, conventional and accelerated conventional) in the parent study and a booster dose before (12\u201318 months post-primary series completion) or at the beginning (3 years post-primary series completion) of the first extension study were screened and enrolled in this study. Blood samples were collected yearly and anti-TBEV antibody response was evaluated by neutralizing test (NT) antibody assays. Analysis was performed overall and per age strata: 15\u201349 years, \u226550 years, and \u226560 years. Results: Of 206 screened individuals, 191 completed the study. Overall, 90\u2013100% of participants in the all-screened set and \u226597% in the per-protocol set had the clinically meaningful threshold of protection (NT titers \u226510) across all timepoints, regardless of the primary vaccination schedule. Overall, antibody geometric mean titers (GMTs) varied from 134 to 343 in the all-screened set. Older age groups showed overall lower GMTs, although GMTs remained higher than NT titers \u226510 up to year 10 in all groups. Conclusion: This study showed long-term persistence of anti-TBEV NT antibodies for up to 10 years after the first booster dose of TBEvac in all age groups, regardless of the primary vaccination schedule.",
    "author_highlights": [
        {
            "endOffset": 12600,
            "sentence": "Additional follow-up of adolescents and adults receiving TBEvac (3-dose primary+1 booster) is ongoing.",
            "startOffset": 12498
        },
        {
            "endOffset": 12701,
            "sentence": "3-dose primary TBEvac and a booster dose elicit a long term immune response up to at least 10 years.",
            "startOffset": 12601
        },
        {
            "endOffset": 12797,
            "sentence": "Conventional, accelerated conventional or rapid primary vaccination schedules are all suitable.",
            "startOffset": 12702
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Goro",
                    "initial": "G.",
                    "last": "Kuno"
                },
                {
                    "first": "Gwong Jen J.",
                    "initial": "G.J.J.",
                    "last": "Chang"
                },
                {
                    "first": "K. Richard",
                    "initial": "K.R.",
                    "last": "Tsuchiya"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Karabatsos"
                },
                {
                    "first": "C. Bruce",
                    "initial": "C.B.",
                    "last": "Cropp"
                }
            ],
            "firstpage": "73",
            "issn": "0022538X",
            "lastpage": "83",
            "pmid": "9420202",
            "pub_year": 1998,
            "title": "Phylogeny of the genus Flavivirus",
            "volume": "72"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Natalia",
                    "initial": "N.",
                    "last": "Kerbo"
                },
                {
                    "first": "Irena",
                    "initial": "I.",
                    "last": "Donchenko"
                },
                {
                    "first": "Kuulo",
                    "initial": "K.",
                    "last": "Kutsar"
                },
                {
                    "first": "Veera",
                    "initial": "V.",
                    "last": "Vasilenko"
                }
            ],
            "firstpage": "E050623.2",
            "issn": "15607917",
            "pmid": "16783104",
            "pub_year": 2005,
            "title": "Tickborne encephalitis outbreak in Estonia linked to raw goat milk, May-June 2005.",
            "volume": "10"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Lindquist"
                },
                {
                    "first": "Olli",
                    "initial": "O.",
                    "last": "Vapalahti"
                }
            ],
            "doi": "10.1016/S0140-6736(08)60800-4",
            "firstpage": "1861",
            "issn": "01406736",
            "lastpage": "1871",
            "pmid": "18514730",
            "pub_year": 2008,
            "title": "Tick-borne encephalitis",
            "volume": "371"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Mats",
                    "initial": "M.",
                    "last": "Haglund"
                },
                {
                    "first": "G\u00f6ran",
                    "initial": "G.",
                    "last": "G\u00fcnther"
                }
            ],
            "doi": "10.1016/S0264-410X(02)00811-3",
            "firstpage": "S11",
            "issn": "0264410X",
            "lastpage": "S18",
            "pmid": "12628810",
            "pub_year": 2003,
            "title": "Tick-borne encephalitis - Pathogenesis, clinical course and long-term follow-up",
            "volume": "21"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Reinhard",
                    "initial": "R.",
                    "last": "Kaiser"
                }
            ],
            "doi": "10.1093/brain/122.11.2067",
            "firstpage": "2067",
            "issn": "00068950",
            "lastpage": "2078",
            "pmid": "10545392",
            "pub_year": 1999,
            "title": "The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98. A prospective study of 656 patients",
            "volume": "122"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Sarah E.",
                    "initial": "S.E.",
                    "last": "Randolph"
                }
            ],
            "doi": "10.1016/j.vetpar.2009.09.011",
            "firstpage": "92",
            "issn": "03044017",
            "lastpage": "94",
            "pmid": "19833440",
            "pub_year": 2010,
            "title": "To what extent has climate change contributed to the recent epidemiology of tick-borne diseases?",
            "volume": "167"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "Ilaria",
                    "initial": "I.",
                    "last": "Galgani"
                },
                {
                    "first": "Eveline M.",
                    "initial": "E.M.",
                    "last": "Bunge"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Hendriks"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Schludermann"
                },
                {
                    "first": "Cinzia",
                    "initial": "C.",
                    "last": "Marano"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "De Moerlooze"
                }
            ],
            "doi": "10.1080/14760584.2017.1358620",
            "firstpage": "919",
            "issn": "14760584",
            "lastpage": "932",
            "pmid": "28770638",
            "pub_year": 2017,
            "title": "Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules",
            "volume": "16"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Beran"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Olaf",
                    "initial": "O.",
                    "last": "Zent"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.06.028",
            "firstpage": "4275",
            "issn": "0264410X",
            "lastpage": "4280",
            "pmid": "24950352",
            "pub_year": 2014,
            "title": "Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety",
            "volume": "32"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Annelie",
                    "initial": "A.",
                    "last": "Plentz"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Jilg"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Hans B.",
                    "initial": "H.B.",
                    "last": "Kuhr"
                },
                {
                    "first": "Olaf",
                    "initial": "O.",
                    "last": "Zent"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.11.082",
            "firstpage": "853",
            "issn": "0264410X",
            "lastpage": "856",
            "pmid": "19071180",
            "pub_year": 2009,
            "title": "Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur\u00ae Adults",
            "volume": "27"
        },
        "b0060": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Sch\u00f6ndorf"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Beran"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Cizkova"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Lesna"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Banzhoff"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Zent"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.10.028",
            "firstpage": "1470",
            "issn": "0264410X",
            "lastpage": "1475",
            "pmid": "17196713",
            "pub_year": 2007,
            "title": "Tick-borne encephalitis (TBE) vaccination: Applying the most suitable vaccination schedule",
            "volume": "25"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Nadine",
                    "initial": "N.",
                    "last": "Litzba"
                },
                {
                    "first": "Hana",
                    "initial": "H.",
                    "last": "Zelen\u00e1"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Kreil"
                },
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Niklasson"
                },
                {
                    "first": "Ilona",
                    "initial": "I.",
                    "last": "K\u00fchlmann-Rabens"
                },
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Remoli"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Niedrig"
                }
            ],
            "doi": "10.1089/vbz.2012.1287",
            "firstpage": "149",
            "issn": "15303667",
            "lastpage": "159",
            "pmid": "24359414",
            "pub_year": 2014,
            "title": "Evaluation of different serological diagnostic methods for tick-borne encephalitis virus: Enzyme-linked immunosorbent, immunofluorescence, and neutralization assay",
            "volume": "14"
        },
        "b0070": {
            "authors": [
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Klockmann"
                },
                {
                    "first": "H. L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Franke"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Hein"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Reiner"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hilfenhaus"
                }
            ],
            "doi": "10.1016/S0092-1157(89)80004-6",
            "firstpage": "331",
            "issn": "00921157",
            "lastpage": "342",
            "pmid": "2613707",
            "pub_year": 1989,
            "title": "Preclinical investigations of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine",
            "volume": "17"
        },
        "b0075": {
            "authors": [
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Zent"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Banzhoff"
                },
                {
                    "first": "A. K.",
                    "initial": "A.K.",
                    "last": "Hilbert"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Meriste"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "S\u0142uzewski"
                },
                {
                    "first": "Ch",
                    "initial": "C.",
                    "last": "Wittermann"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00421-3",
            "firstpage": "3584",
            "issn": "0264410X",
            "lastpage": "3592",
            "pmid": "12922086",
            "pub_year": 2003,
            "title": "Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer",
            "volume": "21"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Olaf",
                    "initial": "O.",
                    "last": "Zent"
                },
                {
                    "first": "Renald",
                    "initial": "R.",
                    "last": "Hennig"
                },
                {
                    "first": "Angelika",
                    "initial": "A.",
                    "last": "Banzhoff"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                }
            ],
            "firstpage": "85",
            "issn": "11951982",
            "lastpage": "93",
            "pmid": "15996453",
            "pub_year": 2005,
            "title": "Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers",
            "volume": "12"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Olaf",
                    "initial": "O.",
                    "last": "Zent"
                },
                {
                    "first": "Annelie",
                    "initial": "A.",
                    "last": "Plentz"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Nikolaus",
                    "initial": "N.",
                    "last": "Fr\u00fchwein"
                },
                {
                    "first": "Hans B.",
                    "initial": "H.B.",
                    "last": "Kuhr"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Broeker"
                },
                {
                    "first": "Angelika",
                    "initial": "A.",
                    "last": "Banzhoff"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Jilg"
                }
            ],
            "doi": "10.1016/j.vaccine.2004.06.007",
            "firstpage": "312",
            "issn": "0264410X",
            "lastpage": "315",
            "pmid": "15530673",
            "pub_year": 2004,
            "title": "TBE booster immunization according to the rapid immunization schedule: Are 3-year booster intervals really necessary?",
            "volume": "23"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Franz X.",
                    "initial": "F.X.",
                    "last": "Heinz"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Holzmann"
                },
                {
                    "first": "Astrid",
                    "initial": "A.",
                    "last": "Essl"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kundi"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.08.024",
            "firstpage": "7559",
            "issn": "0264410X",
            "lastpage": "7567",
            "pmid": "17869389",
            "pub_year": 2007,
            "title": "Field effectiveness of vaccination against tick-borne encephalitis",
            "volume": "25"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Kunz"
                }
            ],
            "doi": "10.1016/S0264-410X(02)00813-7",
            "firstpage": "S50",
            "issn": "0264410X",
            "lastpage": "S55",
            "pmid": "12628814",
            "pub_year": 2003,
            "title": "TBE vaccination and the Austrian experience",
            "volume": "21"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Ursula",
                    "initial": "U.",
                    "last": "Hainz"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Jenewein"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Asch"
                },
                {
                    "first": "Karl P.",
                    "initial": "K.P.",
                    "last": "Pfeiffer"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Berger"
                },
                {
                    "first": "Beatrix",
                    "initial": "B.",
                    "last": "Grubeck-Loebenstein"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.01.085",
            "firstpage": "3232",
            "issn": "0264410X",
            "lastpage": "3235",
            "pmid": "15837226",
            "pub_year": 2005,
            "title": "Insufficient protection for healthy elderly adults by tetanus and TBE vaccines",
            "volume": "23"
        },
        "b0105": {
            "authors": [
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "J\u00edlkov\u00e1"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Vejvalkov\u00e1"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Skorkovsk\u00fd"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Kr\u00e1l"
                }
            ],
            "doi": "10.1517/14712590903066711",
            "firstpage": "797",
            "issn": "14712598",
            "lastpage": "803",
            "pmid": "19527104",
            "pub_year": 2009,
            "title": "Serological response to tick-borne encephalitis (TBE) vaccination in the elderly - Results from an observational study",
            "volume": "9"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Loew-Baselli"
                },
                {
                    "first": "Eva Maria",
                    "initial": "E.M.",
                    "last": "Poellabauer"
                },
                {
                    "first": "Borislava G.",
                    "initial": "B.G.",
                    "last": "Pavlova"
                },
                {
                    "first": "Sandor",
                    "initial": "S.",
                    "last": "Fritsch"
                },
                {
                    "first": "Manuela",
                    "initial": "M.",
                    "last": "Koska"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Bobrovsky"
                },
                {
                    "first": "Ryszard",
                    "initial": "R.",
                    "last": "Konior"
                },
                {
                    "first": "Hartmut J.",
                    "initial": "H.J.",
                    "last": "Ehrlich"
                }
            ],
            "doi": "10.4161/hv.5.8.8571",
            "firstpage": "551",
            "issn": "15548600",
            "lastpage": "556",
            "pmid": "19430202",
            "pub_year": 2009,
            "title": "Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN\u00ae 0.5 ml in adults aged 18-67 years",
            "volume": "5"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Herwig",
                    "initial": "H.",
                    "last": "Kollaritsch"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Paulke-Korinek"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Holzmann"
                },
                {
                    "first": "Joachim",
                    "initial": "J.",
                    "last": "Hombach"
                },
                {
                    "first": "Bjarne",
                    "initial": "B.",
                    "last": "Bjorvatn"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Barrett"
                }
            ],
            "doi": "10.1586/erv.12.86",
            "firstpage": "1103",
            "issn": "14760584",
            "lastpage": "1119",
            "pmid": "23151167",
            "pub_year": 2012,
            "title": "Vaccines and vaccination against tick-borne encephalitis",
            "volume": "11"
        },
        "b0120": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Konior"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Brzostek"
                },
                {
                    "first": "E. M.",
                    "initial": "E.M.",
                    "last": "Poellabauer"
                },
                {
                    "first": "Q.",
                    "initial": "Q.",
                    "last": "Jiang"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Harper"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Erber"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.059",
            "firstpage": "3607",
            "issn": "0264410X",
            "lastpage": "3613",
            "pmid": "28545923",
            "pub_year": 2017,
            "title": "Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5\u00a0mL in adults",
            "volume": "35"
        },
        "b9005": {
            "authors": [
                {
                    "first": "Ursula",
                    "initial": "U.",
                    "last": "Kunze"
                },
                {
                    "first": "Jerneja",
                    "initial": "J.",
                    "last": "Ahcan"
                },
                {
                    "first": "Ashild",
                    "initial": "A.",
                    "last": "Andreassen"
                },
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "Asp\u00f6ck"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Berglund"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Chitimia-Dobler"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Claus Bohn",
                    "initial": "C.B.",
                    "last": "Christiansen"
                },
                {
                    "first": "Renata",
                    "initial": "R.",
                    "last": "Ciupek"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Dautel"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Dobler"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Duscher"
                },
                {
                    "first": "Jonas",
                    "initial": "J.",
                    "last": "Ekwall"
                },
                {
                    "first": "Mona Lisa",
                    "initial": "M.L.",
                    "last": "Engmann"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Haditsch"
                },
                {
                    "first": "Mats",
                    "initial": "M.",
                    "last": "Haglund"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Hansmann"
                },
                {
                    "first": "Franz Xaver",
                    "initial": "F.X.",
                    "last": "Heinz"
                },
                {
                    "first": "Henrieta",
                    "initial": "H.",
                    "last": "Hudeckova"
                },
                {
                    "first": "Neda",
                    "initial": "N.",
                    "last": "Hudopisk"
                },
                {
                    "first": "Anu",
                    "initial": "A.",
                    "last": "J\u00e4\u00e4skel\u00e4inen"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Jilkova"
                },
                {
                    "first": "Olaf",
                    "initial": "O.",
                    "last": "Kahl"
                },
                {
                    "first": "Ivan",
                    "initial": "I.",
                    "last": "Kauzlaric"
                },
                {
                    "first": "Jana",
                    "initial": "J.",
                    "last": "Kerlik"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Kimmig"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Kulcs\u00e1r"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kunze"
                },
                {
                    "first": "Andr\u00e1s",
                    "initial": "A.",
                    "last": "Lakos"
                },
                {
                    "first": "Karl Johan",
                    "initial": "K.J.",
                    "last": "Lidefelt"
                },
                {
                    "first": "Ute",
                    "initial": "U.",
                    "last": "Mackenstedt"
                },
                {
                    "first": "Rasti",
                    "initial": "R.",
                    "last": "Madar"
                },
                {
                    "first": "Aukse",
                    "initial": "A.",
                    "last": "Mickiene"
                },
                {
                    "first": "Masyar",
                    "initial": "M.",
                    "last": "Monazahian"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Niedrig"
                },
                {
                    "first": "Rainer",
                    "initial": "R.",
                    "last": "Oehme"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Paulke-Korinek"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Pfeffer"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Platonov"
                },
                {
                    "first": "Klara",
                    "initial": "K.",
                    "last": "Posfay-Barbe"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Prelog"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Birger",
                    "initial": "B.",
                    "last": "Sandell"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Sebastian"
                },
                {
                    "first": "Zoran",
                    "initial": "Z.",
                    "last": "Simonovic"
                },
                {
                    "first": "Gerold",
                    "initial": "G.",
                    "last": "Stanek"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Steffen"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stefkovicov\u00e1"
                },
                {
                    "first": "Franc",
                    "initial": "F.",
                    "last": "Strle"
                },
                {
                    "first": "Dasa",
                    "initial": "D.",
                    "last": "Stupica"
                },
                {
                    "first": "Mikael",
                    "initial": "M.",
                    "last": "Sundin"
                },
                {
                    "first": "Jochen",
                    "initial": "J.",
                    "last": "S\u00fcss"
                },
                {
                    "first": "Pille",
                    "initial": "P.",
                    "last": "Taba"
                },
                {
                    "first": "Elina",
                    "initial": "E.",
                    "last": "Tonteri"
                },
                {
                    "first": "Antti",
                    "initial": "A.",
                    "last": "Vaheri"
                },
                {
                    "first": "Ursula",
                    "initial": "U.",
                    "last": "Wiedermann-Schmidt"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Zajkowska"
                },
                {
                    "first": "Dace",
                    "initial": "D.",
                    "last": "Zavadska"
                },
                {
                    "first": "Werner",
                    "initial": "W.",
                    "last": "Zenz"
                },
                {
                    "first": "Milda",
                    "initial": "M.",
                    "last": "Zygutiene"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.ttbdis.2015.04.005",
            "firstpage": "545",
            "issn": "1877959X",
            "lastpage": "548",
            "pmid": "26025269",
            "pub_year": 2015,
            "title": "Tick-borne encephalitis as a notifiable disease - Status quo and the way forward. Report of the 17th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE)",
            "volume": "6"
        }
    },
    "body_text": [
        {
            "endOffset": 31686,
            "parents": [],
            "secId": "s0050",
            "sentence": "Encepur Adults is a trademark owned by the GSK group of companies.",
            "startOffset": 31620,
            "title": "Trademark statement"
        },
        {
            "endOffset": 22216,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In this set, missing antibody values were set to half of the LLOD (i.e., an NT titer of 1) and used in the analyses.",
            "startOffset": 22100,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23904,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The main reasons for exclusions from the PPS were: lost to follow up (n = 5) administration of any medication or concomitant vaccine(s) specified in the protocol (n = 3), missing serological results (n = 4), failure to comply with the blood draw schedule (n = 2) or to meet the entry criteria (n = 6) and NT titer < 10 (n = 1).",
            "startOffset": 23577,
            "title": "Study population"
        },
        {
            "endOffset": 20750,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial is registered at ClinicalTrials.gov (NCT01562444).",
            "startOffset": 20690,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26853,
            "parents": [],
            "secId": "s0045",
            "sentence": "These results confirm the long-term persistence of an immune response against TBEV, as measured by the percentage of participants with NT titers above a chosen clinically meaningful threshold.",
            "startOffset": 26661,
            "title": "Discussion"
        },
        {
            "endOffset": 20949,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Blood samples (approximately 10 ml) were drawn once a year, from year 6 up to year 10 from the first extension study, allowing for a window of 30 days for the collection of each sample.",
            "startOffset": 20764,
            "title": "Assessments"
        },
        {
            "endOffset": 23272,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The kinetics of long-term antibody titers of the booster response were evaluated by summary statistics only and no tests for group comparisons were planned.",
            "startOffset": 23116,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27759,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 27758,
                    "startOffset": 27754
                }
            },
            "secId": "s0045",
            "sentence": "Increasing age is the most important predictive parameter for lower antibody titers and has been associated with a stronger decline in anti-TBEV post-vaccination antibody levels [21].",
            "startOffset": 27576,
            "title": "Discussion"
        },
        {
            "endOffset": 23319,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "All NT results were interpreted descriptively.",
            "startOffset": 23273,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16572,
            "parents": [],
            "secId": "s0005",
            "sentence": "The polygeline-free inactivated TBE vaccine TBEvac (Encepur Adults, GSK) is licensed for use in adults and adolescents from 12 years of age in Europe.",
            "startOffset": 16422,
            "title": "Introduction"
        },
        {
            "endOffset": 17068,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 16898,
                    "startOffset": 16895
                },
                "b0050": {
                    "endOffset": 16992,
                    "startOffset": 16985
                },
                "b0055": {
                    "endOffset": 16992,
                    "startOffset": 16985
                }
            },
            "secId": "s0005",
            "sentence": "Although the vaccine was shown to be immunogenic and well-tolerated in adults [9] and antibody persistence up to 5 years post-booster vaccination has been demonstrated [10,11], long-term protection afforded beyond this period was not assessed to date.",
            "startOffset": 16817,
            "title": "Introduction"
        },
        {
            "endOffset": 16118,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16117,
                    "startOffset": 16114
                }
            },
            "secId": "s0005",
            "sentence": "The incidence of TBE follows a seasonal pattern that corresponds to periods of outdoor activities and tick activity, with peaks in spring, summer and autumn [2].",
            "startOffset": 15957,
            "title": "Introduction"
        },
        {
            "endOffset": 25171,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "During the 5 years of follow up, NT GMTs varied between 134 and 343 and between 222 and 396 across the 3 groups in the all-screened set and PPS, respectively (Table 4).",
            "startOffset": 25003,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26660,
            "parents": [],
            "secId": "s0045",
            "sentence": "Overall, \u226590% of individuals in the all-screened set having received primary vaccination and a booster dose of TBEvac, and \u226598% in the PPS still had NT titers \u226510 10 years post-booster, regardless of the primary immunization schedule received.",
            "startOffset": 26417,
            "title": "Discussion"
        },
        {
            "endOffset": 28505,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 28504,
                    "startOffset": 28500
                }
            },
            "secId": "s0045",
            "sentence": "Only 2 participants could not maintain NT titers \u226510 from 6 to 10 years post-booster vaccination and 1 additional individual had NT titers <10 during the first extension study [10].",
            "startOffset": 28324,
            "title": "Discussion"
        },
        {
            "endOffset": 20541,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The second extension study was carried out in accordance with the Declaration of Helsinki and conformed to the International Conference on Harmonization-Good Clinical Practice guidelines, as well as local regulatory requirements.",
            "startOffset": 20312,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24068,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The mean age at enrollment was 42.3 \u00b1 14.5 years.",
            "startOffset": 24019,
            "title": "Study population"
        },
        {
            "endOffset": 22099,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The main analyses for immunogenicity were based on the all-screened set, which included all screening failures and those who withdrew from the study.",
            "startOffset": 21950,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 25260,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Overall, GMTs remained similar across groups and within the assay variability (Table 4).",
            "startOffset": 25172,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30108,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 30107,
                    "startOffset": 30103
                }
            },
            "secId": "s0045",
            "sentence": "A recent study also evaluated seropersistence of anti-TBEV antibodies in adults 10 years after a first booster vaccination [25].",
            "startOffset": 29980,
            "title": "Discussion"
        },
        {
            "endOffset": 24866,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Only 2 participants presented NT titers <10 during the study, one in the 15\u201349 years age stratum (Group A) and one in the \u226560 years age stratum (Group C).",
            "startOffset": 24712,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 18804,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Of these, 206 individuals who had received one of the 3 licensed vaccination schedules (Groups R, C and A) were invited to participate in the second extension study, which evaluated the persistence of antibody response elicited by the booster dose from 6 years up to 10 years post-last vaccination (Fig. 2).",
            "startOffset": 18497,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31890,
            "parents": [],
            "secId": "s0055",
            "sentence": "The study was supported by the Novartis Vaccines Division; on 2 March 2015 Novartis\u2019 non-influenza Vaccines Business was acquired by the GSK group of companies.",
            "startOffset": 31730,
            "title": "Funding"
        },
        {
            "endOffset": 18159,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 18149,
                    "startOffset": 18145
                }
            },
            "secId": "s0015",
            "sentence": "In the parent study, 398 healthy adolescents and adults aged \u226512 years had received 3 primary TBEvac doses according to a licensed (rapid [Group R]; conventional [Group C]; accelerated conventional [Group A]) or an unlicensed (modified conventional [Group M]) vaccination schedule [12] (Fig. 2).",
            "startOffset": 17864,
            "title": "Study design and participants"
        },
        {
            "endOffset": 21879,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Within-group geometric mean ratios (GMRs) were also calculated using 2 different baselines as denominators: either the pre-booster (excluding individuals from Group Rv of the first extension study) or the post-booster vaccination GMT (calculated on the first day of the first extension study for Group Rv and 21 days post-booster dose for Groups R, C and A).",
            "startOffset": 21521,
            "title": "Assessments"
        },
        {
            "endOffset": 23576,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The PPS included 92\u201396% (190/206\u2013198/206) of the all-screened set across the 5 years of follow-up.",
            "startOffset": 23478,
            "title": "Study population"
        },
        {
            "endOffset": 29406,
            "parents": [],
            "secId": "s0045",
            "sentence": "In antibody persistence studies, un-observable data due to dropouts or early terminations may lead to biased estimates, as these missing data are missing not at random (MNAR).",
            "startOffset": 29231,
            "title": "Discussion"
        },
        {
            "endOffset": 24315,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In the all-screened set, the percentage of individuals with NT titers \u22652 varied from 96 to 100% at Year 6, and from 90 to 96% at Year 10, among all groups.",
            "startOffset": 24160,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22576,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Analyses were also performed on the per-protocol set (PPS) at each timepoint, which included enrolled participants with an evaluable serum sample at the relevant timepoint, and not meeting pre-specified exclusion criteria (for example, NT titers <10, confirmed exposure to TBEV or other flaviviruses, documented TBE or flavivirus vaccination during the study).",
            "startOffset": 22216,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 21927,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "No safety endpoints were assessed in this study.",
            "startOffset": 21879,
            "title": "Assessments"
        },
        {
            "endOffset": 15558,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15557,
                    "startOffset": 15554
                }
            },
            "secId": "s0005",
            "sentence": "TBE is a serious acute infection of the central nervous system that can lead to death or long-term neurological sequelae [4].",
            "startOffset": 15433,
            "title": "Introduction"
        },
        {
            "endOffset": 28107,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 28057,
                    "startOffset": 28053
                }
            },
            "secId": "s0045",
            "sentence": "Nevertheless, it is noteworthy that NT GMTs were \u226557 across all groups until Year 10 and that, in contrast to published data [24], the decline was not stronger with increased age.",
            "startOffset": 27928,
            "title": "Discussion"
        },
        {
            "endOffset": 22888,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "GMTs, GMRs and 95% CIs were calculated using an analysis of variance method with logarithmically transformed titers/ratio values.",
            "startOffset": 22759,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was also approved by a local Ethics Review Committee and written informed consent was obtained from all participants prior to enrollment.",
            "startOffset": 20542,
            "title": "Study design and participants"
        },
        {
            "endOffset": 21234,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The NT was performed at the GSK Clinical Science Laboratory in Marburg, Germany.",
            "startOffset": 21154,
            "title": "Assessments"
        },
        {
            "endOffset": 27576,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 27575,
                    "startOffset": 27568
                },
                "b9005": {
                    "endOffset": 27575,
                    "startOffset": 27568
                }
            },
            "secId": "s0045",
            "sentence": "The mass vaccination program initiated more than 30 years ago has resulted in a profound drop in TBE cases when compared to Czechia, where endemic areas are similar and TBE surveillance is excellent but vaccination coverage is low (23%) [19,20].",
            "startOffset": 27331,
            "title": "Discussion"
        },
        {
            "endOffset": 29980,
            "parents": [],
            "secId": "s0045",
            "sentence": "We observed that immune response to TBEvac (NT titers \u226510) persists in an estimated 90 and 98% of vaccinees in the all-screened set and PPS, respectively, following different immunization schedules.",
            "startOffset": 29782,
            "title": "Discussion"
        },
        {
            "endOffset": 28324,
            "parents": [],
            "secId": "s0045",
            "sentence": "Although the sample size was small for this age group, this suggests a long-term immunity against TBE of up to 10 years, which may point towards an extension of the booster intervals for elderly individuals, as well.",
            "startOffset": 28108,
            "title": "Discussion"
        },
        {
            "endOffset": 15808,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0030": {
                    "endOffset": 15807,
                    "startOffset": 15802
                }
            },
            "secId": "s0005",
            "sentence": "Up to 30% of adults with clinical evidence of infection are believed to develop meningitis, meningoencephalitis or, more rarely, encephalomyelitis/radiculitis, while meningitis is the predominant reported neurological complication in children [5,6].",
            "startOffset": 15559,
            "title": "Introduction"
        },
        {
            "endOffset": 31227,
            "parents": [],
            "secId": "s0045",
            "sentence": "In conclusion, based on data from a continuous 15-year follow-up, participants are protected against TBE, regardless of the schedule used and the age at immunization.",
            "startOffset": 31061,
            "title": "Discussion"
        },
        {
            "endOffset": 20180,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In addition, all participants were re-assessed for continued eligibility in the study, and a physical examination and documentation of medical history and concomitant medications taken were performed on a yearly basis.",
            "startOffset": 19962,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25003,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Within the same group, the percentage of participants with NT titers \u226510 across all timepoints did not seem to differ with age (Fig. S1).",
            "startOffset": 24866,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28616,
            "parents": [],
            "secId": "s0045",
            "sentence": "The latter was screened and included in the all-screened set of the present extension study, but not enrolled.",
            "startOffset": 28506,
            "title": "Discussion"
        },
        {
            "endOffset": 23425,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "Of the 206 screened individuals, 201 were enrolled and 191 completed the study.",
            "startOffset": 23346,
            "title": "Study population"
        },
        {
            "endOffset": 29072,
            "parents": [],
            "secId": "s0045",
            "sentence": "This study enabled the long-term monitoring of NT titers with high compliance rate, as a high percentage of participants from the parent study were retained over the course of 15 years and 191 out of 213 participants who received the first booster dose completed this 10-year follow-up.",
            "startOffset": 28786,
            "title": "Discussion"
        },
        {
            "endOffset": 27330,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 27329,
                    "startOffset": 27325
                }
            },
            "secId": "s0045",
            "sentence": "Reports from Austria serve as the most reliable data source concerning the effectiveness of TBE vaccination [18].",
            "startOffset": 27217,
            "title": "Discussion"
        },
        {
            "endOffset": 21365,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 21364,
                    "startOffset": 21357
                },
                "b0085": {
                    "endOffset": 21364,
                    "startOffset": 21357
                }
            },
            "secId": "s0020",
            "sentence": "The lowest limit of detection (LLOD) for the NT assay was 2; NT titers \u226510 were considered a clinical meaningful threshold [16,17].",
            "startOffset": 21234,
            "title": "Assessments"
        },
        {
            "endOffset": 16377,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccination is considered an effective prophylaxis against TBE, as no specific antiviral exists.",
            "startOffset": 16281,
            "title": "Introduction"
        },
        {
            "endOffset": 31601,
            "parents": [],
            "secId": "s0045",
            "sentence": "The results of this second 5-year extension study are similar to those of the 5-year follow-up post-booster dose, suggesting that the conventional, accelerated conventional or rapid schedules are all appropriate primary vaccination schedules and that 4 doses of TBEvac administered as a 3-dose primary vaccination and a booster dose afford protection for at least 10 years.",
            "startOffset": 31228,
            "title": "Discussion"
        },
        {
            "endOffset": 17682,
            "parents": [],
            "secId": "s0005",
            "sentence": "A summary contextualizing the results and potential clinical research relevance and impact is displayed in the Focus on Patient Section (Fig. 1) for the benefit of Health Care Professionals.",
            "startOffset": 17492,
            "title": "Introduction"
        },
        {
            "endOffset": 16281,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16280,
                    "startOffset": 16275
                },
                "b0040": {
                    "endOffset": 16280,
                    "startOffset": 16275
                }
            },
            "secId": "s0005",
            "sentence": "Climate changes have led to prolonged periods of TBE occurrence in endemic areas and an expansion of the TBEV to new foci in previously non-endemic regions [7,8].",
            "startOffset": 16119,
            "title": "Introduction"
        },
        {
            "endOffset": 23116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For each group, analyses were repeated in the following age strata, defined based on the participants\u2019 age at the start of the first extension study: 15\u201349 years, \u226550 years, and \u226560 years (a subset of the \u226550 years age stratum).",
            "startOffset": 22888,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29781,
            "parents": [],
            "secId": "s0045",
            "sentence": "Therefore, in this study, we also presented the persistence results in the all-screened set using an imputation of missing MNAR data which assumed any un-observable antibody results as below the LLOQ, thus under-estimating true antibody persistence.",
            "startOffset": 29532,
            "title": "Discussion"
        },
        {
            "endOffset": 19348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Individuals were excluded from the second extension study if they had a NT titer <10 before the first study visit, had received a TBE or other flavivirus (e.g. yellow fever, dengue fever, Japanese encephalitis) vaccine between the completion of the first extension study and the start of the current trial, had a previous confirmed TBEV infection or were exposed to other flaviviruses, had received any investigational or non-registered product within 28 days prior to enrollment or expected to receive one prior to the completion of the study.",
            "startOffset": 18804,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26417,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 26416,
                    "startOffset": 26412
                },
                "b0060": {
                    "endOffset": 26294,
                    "startOffset": 26290
                }
            },
            "secId": "s0045",
            "sentence": "This study is the first to assess the persistence of antibody levels from 6 up to 10 years post-booster vaccination with TBEvac in individuals who had previously received either the conventional, accelerated conventional, or rapid primary vaccination schedules [12], and expands the results of the previous study assessing antibody persistence up to 5 years post-booster vaccination [10].",
            "startOffset": 26029,
            "title": "Discussion"
        },
        {
            "endOffset": 21520,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Immunogenicity results were expressed as the percentage of participants with NT titers \u22652 and \u226510 and geometric mean antibody titers (GMTs) in each group.",
            "startOffset": 21366,
            "title": "Assessments"
        },
        {
            "endOffset": 24143,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The demographic characteristics were well-balanced among groups (Table 1).",
            "startOffset": 24069,
            "title": "Study population"
        },
        {
            "endOffset": 17223,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 17222,
                    "startOffset": 17215
                },
                "b0055": {
                    "endOffset": 17222,
                    "startOffset": 17215
                }
            },
            "secId": "s0005",
            "sentence": "Data collected at 5 years after booster vaccination showed that antibody titers measured by neutralization test (NT) were persistently high (\u226510) [10,11].",
            "startOffset": 17069,
            "title": "Introduction"
        },
        {
            "endOffset": 17492,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 17491,
                    "startOffset": 17487
                },
                "b0060": {
                    "endOffset": 17392,
                    "startOffset": 17388
                }
            },
            "secId": "s0005",
            "sentence": "Therefore, the objective of the current study was to evaluate the persistence of antibody response through 6\u201310 years after different primary vaccination schedules [12] and a first booster with TBE vaccine at 12\u201318 months or 3 years following primary vaccination [10].",
            "startOffset": 17224,
            "title": "Introduction"
        },
        {
            "endOffset": 27046,
            "parents": [],
            "secId": "s0045",
            "sentence": "Our yearly screening and assessments seem to indicate that no participant was infected with TBEV during the study, as convalescent samples would have been detected by spikes in antibody levels.",
            "startOffset": 26853,
            "title": "Discussion"
        },
        {
            "endOffset": 19961,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Additional exclusion criteria were: any vaccination within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study, the presence of a condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objective, chronic immunosuppressive conditions and treatment with immunosuppressants, systemic corticosteroids or immunoglobulins within 4 weeks prior to enrollment or during the study period (except short term use of topical corticosteroids), and receipt of whole blood or plasma derivatives up to 3 months before enrollment.",
            "startOffset": 19349,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27216,
            "parents": [],
            "secId": "s0045",
            "sentence": "However, it is uncertain whether the participants in our study were simply not exposed to TBEV infection or if the data provide evidence for the effectiveness of TBEvac.",
            "startOffset": 27047,
            "title": "Discussion"
        },
        {
            "endOffset": 24711,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The percentages of participants with NT titers \u226510 were \u226598% in the PPS in each of the groups (Table 3).",
            "startOffset": 24607,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25933,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "At Year 10, across all groups GMR values ranged from 0.76 to 1.08 and from 1.12 to 2.89 in the all-screened set and the PPS, respectively, when calculated relative to pre-booster antibody levels, and were lower when computed relative to antibody levels at 21 days post-booster dose (Table S1).",
            "startOffset": 25640,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25490,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "NT GMT values seemed to decrease with increasing age, but remained similar within the same age strata at each timepoint, although the number of individuals was small in the \u226560 years age group (3\u20137 individuals per vaccine group).",
            "startOffset": 25261,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 15433,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 15432,
                    "startOffset": 15429
                }
            },
            "secId": "s0005",
            "sentence": "In the latter cases, infections occur rapidly and often affect groups of people at the same time [3].",
            "startOffset": 15332,
            "title": "Introduction"
        },
        {
            "endOffset": 28786,
            "parents": [],
            "secId": "s0045",
            "sentence": "Only one participant was \u226560 years old, while the other belonged to the 15\u201349 years age group, suggesting that age was not the only factor for the lower titers observed.",
            "startOffset": 28617,
            "title": "Discussion"
        },
        {
            "endOffset": 27927,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 27794,
                    "startOffset": 27787
                },
                "b0105": {
                    "endOffset": 27794,
                    "startOffset": 27787
                },
                "b0110": {
                    "endOffset": 27794,
                    "startOffset": 27787
                }
            },
            "secId": "s0045",
            "sentence": "In line with other reports [21\u201323], overall lower GMTs were observed in the current extension study in individuals \u226550 and \u226560 years of age compared to younger adults.",
            "startOffset": 27760,
            "title": "Discussion"
        },
        {
            "endOffset": 24526,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "At all timepoints, all individuals with NT \u22652 also had NT \u226510, with 1 exception in Group A at Year 8 (60 years of age at booster dose) and 1 exception in Group C at Year 10 (36 years at booster dose) (Table 2).",
            "startOffset": 24316,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22758,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The percentages of individuals with NT titers \u22652 and \u226510 were tabulated by vaccine schedule and timepoint together with their Clopper-Pearson 95%, 2-sided confidence intervals (CIs).",
            "startOffset": 22576,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 17863,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase IV, open-label, single-center second extension study (NCT01562444) was conducted between March 2012 and September 2016 in Czechia.",
            "startOffset": 17722,
            "title": "Study design and participants"
        },
        {
            "endOffset": 15956,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15936,
                    "startOffset": 15933
                }
            },
            "secId": "s0005",
            "sentence": "Case-fatality rates of \u226520% for the Far-Eastern subtype, 6\u2013\u22648% for the Siberian subtype, and 1\u2013\u22642% for the European subtype [2] have been reported.",
            "startOffset": 15809,
            "title": "Introduction"
        },
        {
            "endOffset": 24606,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Results for the PPS were consistent with those observed in the all-screened set.",
            "startOffset": 24526,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30721,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 30529,
                    "startOffset": 30525
                }
            },
            "secId": "s0045",
            "sentence": "In addition, only 68% of individuals in the TicoVac study completed 10-year follow-up without booster dose [25], whereas only 3 out of 216 individuals in the all-screened set from this study had confirmed NT antibody levels <10 and received the second TBEvac booster dose during the course of the study.",
            "startOffset": 30418,
            "title": "Discussion"
        },
        {
            "endOffset": 16816,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16815,
                    "startOffset": 16812
                }
            },
            "secId": "s0005",
            "sentence": "There are several different schedules for primary vaccination against TBE and a first booster dose is generally given at either 12\u201318 months or 3 years after the completion of primary vaccination, depending on the primary schedule applied [2].",
            "startOffset": 16573,
            "title": "Introduction"
        },
        {
            "endOffset": 15331,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15330,
                    "startOffset": 15327
                }
            },
            "secId": "s0005",
            "sentence": "The TBEV is transmitted to humans by a bite from an infected tick or, more rarely, from ingesting the unpasteurized milk and milk products of infected animals [2].",
            "startOffset": 15168,
            "title": "Introduction"
        },
        {
            "endOffset": 21086,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 21035,
                    "startOffset": 21031
                },
                "b0070": {
                    "endOffset": 21085,
                    "startOffset": 21078
                },
                "b0075": {
                    "endOffset": 21085,
                    "startOffset": 21078
                }
            },
            "secId": "s0020",
            "sentence": "Immune response to TBEvac was assessed at each timepoint by a validated NT assay [13], which was previously described in detail [14,15].",
            "startOffset": 20950,
            "title": "Assessments"
        },
        {
            "endOffset": 24018,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "A higher percentage of females (54%; 111/205) than males were screened and all participants were White/Caucasian.",
            "startOffset": 23905,
            "title": "Study population"
        },
        {
            "endOffset": 15167,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 15166,
                    "startOffset": 15163
                }
            },
            "secId": "s0005",
            "sentence": "Tick-borne encephalitis (TBE) is caused by the TBE virus (TBEV), a member of the Flaviviridae family, which comprises about 70 species including the dengue, yellow fever, Japanese encephalitis and West Nile viruses [1].",
            "startOffset": 14948,
            "title": "Introduction"
        },
        {
            "endOffset": 16421,
            "parents": [],
            "secId": "s0005",
            "sentence": "Treatment is based on symptomatic measures.",
            "startOffset": 16378,
            "title": "Introduction"
        },
        {
            "endOffset": 29531,
            "parents": [],
            "secId": "s0045",
            "sentence": "PPSs generally exclude participants with these MNAR missing data, so analysis using PPS over-estimates the true persistence.",
            "startOffset": 29407,
            "title": "Discussion"
        },
        {
            "endOffset": 31061,
            "parents": [],
            "secId": "s0045",
            "sentence": "Limitations of the study include the relatively small sample sizes for some of the age-stratified data analyses in older adults (\u226560 years), which might preclude generalization of our findings for this age subset.",
            "startOffset": 30848,
            "title": "Discussion"
        },
        {
            "endOffset": 31723,
            "parents": [],
            "secId": "s0050",
            "sentence": "FSME-IMMUN is a trademark of Pfizer.",
            "startOffset": 31687,
            "title": "Trademark statement"
        },
        {
            "endOffset": 23477,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "Reasons for early termination are listed in Fig. 2.",
            "startOffset": 23426,
            "title": "Study population"
        },
        {
            "endOffset": 21153,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The same assay was used in the parent and first extension studies.",
            "startOffset": 21087,
            "title": "Assessments"
        },
        {
            "endOffset": 29230,
            "parents": [],
            "secId": "s0045",
            "sentence": "This, together with the use of the all-screened set to assess the long-term persistence of anti-TBEV antibodies, constitutes the main strengths of our study.",
            "startOffset": 29073,
            "title": "Discussion"
        },
        {
            "endOffset": 20312,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Any participants with an NT titer <10 who were discontinued from the trial were offered a booster dose of TBEvac outside the study.",
            "startOffset": 20181,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30417,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 30416,
                    "startOffset": 30409
                },
                "b0055": {
                    "endOffset": 30416,
                    "startOffset": 30409
                },
                "b0120": {
                    "endOffset": 30199,
                    "startOffset": 30195
                }
            },
            "secId": "s0045",
            "sentence": "The percentage of participants demonstrating NT titers \u226510 was lower (85%) in the PPS [25] following administration of TicoVac (FSME-Immun, Pfizer), another widely used vaccine against TBE, and GMTs also declined more significantly than what was observed in this and other TBEvac persistence studies [10,11].",
            "startOffset": 30109,
            "title": "Discussion"
        },
        {
            "endOffset": 18496,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 18495,
                    "startOffset": 18491
                }
            },
            "secId": "s0015",
            "sentence": "In the first extension study (NCT00387634), 283 previously primed participants received a booster dose of TBEvac 3 years post-primary vaccination, while 40 participants (from Group R in the parent study) received it prior to enrollment at 16\u201318 months post-primary vaccination (Group Rv); all participants were followed for 5 years [10].",
            "startOffset": 18159,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25640,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In the all-screened set, GMTs were \u2265151, \u226598 and \u226557 until Year 10 in participants aged 15\u201349 years, \u226550 years and \u226560 years, respectively (Fig. S2).",
            "startOffset": 25491,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26018,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Similar trends were observed when GMRs were analyzed by age stratum (Tables S2, S3).",
            "startOffset": 25934,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30848,
            "parents": [],
            "secId": "s0045",
            "sentence": "Therefore, the findings from our study should be considered as vaccine-specific, and cannot be extended to other TBE vaccines.",
            "startOffset": 30722,
            "title": "Discussion"
        },
        {
            "endOffset": 32029,
            "parents": [],
            "secId": "s0055",
            "sentence": "GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 31891,
            "title": "Funding"
        }
    ],
    "docId": "S0264410X18300227",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "jiri.beran@vakcinace.cz",
                "first": "Jiri",
                "initial": "J.",
                "last": "Beran"
            },
            {
                "email": "maria.x.lattanzi@gsk.com",
                "first": "Maria",
                "initial": "M.",
                "last": "Lattanzi"
            },
            {
                "email": "fang.z.xie@gsk.com",
                "first": "Fang",
                "initial": "F.",
                "last": "Xie"
            },
            {
                "email": "luca.x.moraschini@gsk.com",
                "first": "Luca",
                "initial": "L.",
                "last": "Moraschini"
            },
            {
                "email": "ilaria.x.galgani@gsk.com",
                "first": "Ilaria",
                "initial": "I.",
                "last": "Galgani"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.12.081",
        "firstpage": "4623",
        "issn": "0264410X",
        "keywords": [
            "Adults",
            "Booster",
            "Encepur",
            "Long-term persistence",
            "Tick-borne encephalitis"
        ],
        "lastpage": "4629",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10\u202fyears antibody persistence"
    }
}